News
Gilead’s Yeztugo offers 6-month HIV protection and becomes the first PrEP injection approved for twice-yearly use.
WASHINGTON — (AP) — The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated ...
On Wednesday, the Food and Drug Administration approved a highly effective, injectable drug to help prevent the transmission ...
It reduces transmissions by up to 96%, but now world governments and big-dollar funders will need to step in.
A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One looming question: Will it be affordable for lower resource countries?
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...
Health-care companies were flat as traders hedged their bets on the outlook for interest rates. Gilead Sciences ticked down even after it won Food and Drug Administration approval for a highly ...
In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.
The Food and Drug Administration on Wednesday granted approval for Gilead Sciences’ twice-yearly injectable HIV prevention ...
The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results